Analyst John Nelson downgraded WPX from Buy to Neutral and maintained a $21 price target. The analyst removed the stock from Goldman's Americas Conviction List.
Since its Feb. 1 addition to the Americas Conviction List, WPX shares have gained about 27 percent, better than S&P 500's 26-percent advance and the SPDR S&P Oil & Gas Explore & Prod. (ETF) (NYSE: XOP)'s 12-percent gain, Nelson said in the Friday downgrade note. (See the analyst's track record here.)
With the valuation now less differentiated and the stock trading merely 8 percent below the price target compared to the 5-percent average and 8-percent median for Goldman's SMID E&P coverage universe, the analyst said a Neutral rating seems apt.
WPX's secular growth outlook remains intact, and the company possesses the potential to grow oil volumes at a CAGR of over 20 percent over the next three years and generate free cash flow at $55/barrel for WTI crude oil.
"Over the last four years WPX has executed a near-complete asset base repositioning, recapitalized its balance sheet and unlocked shareholder value by being an early mover to Permian midstream investments," Nelson said.
The Price Action
WPX shares were sliding 2.56 percent to $19.01 at the time of publication Friday.
Exploring E&P ETFs As Earnings Plays
A Pair Trade In E&P: Bernstein Upgrades ConocoPhillips, Downgrades Concho
Latest Ratings for WPX
|Aug 2018||Goldman Sachs||Downgrades||Buy||Neutral|
|Aug 2018||Bank of America||Maintains||Buy||Buy|
|Jul 2018||TD Securities||Initiates Coverage On||Buy|
View More Analyst Ratings for WPX
View the Latest Analyst Ratings
See more from Benzinga
- The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings
- The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter
- Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.